LSM2 and systemic sclerosis: However, recent data of the SSc-ILD patients with anti-U1-snRNP antibodies have worse baseline lung function, with a lower mean forced vital capacity (82.0% vs. 86.0%, p < 0.001) and diffusing capacity for carbon monoxide (57.0% vs. 60.5%, p = 0.003).